These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Intermittent endocrine treatment. Van Cangh PJ; Tombal B; Gala JL World J Urol; 2000 Jun; 18(3):183-9. PubMed ID: 10926082 [TBL] [Abstract][Full Text] [Related]
3. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153 [TBL] [Abstract][Full Text] [Related]
4. The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer. Gleave M; Klotz L; Taneja SS Urol Oncol; 2009; 27(1):81-6. PubMed ID: 19111804 [TBL] [Abstract][Full Text] [Related]
6. The role of intermittent androgen deprivation in prostate cancer. Boccon-Gibod L; Hammerer P; Madersbacher S; Mottet N; Prayer-Galetti T; Tunn U BJU Int; 2007 Oct; 100(4):738-43. PubMed ID: 17662079 [No Abstract] [Full Text] [Related]
7. [The question of intermittent hormonal treatment of cancer of the prostate]. Boca P Acta Urol Belg; 1998 May; 66(2):17-20. PubMed ID: 9633121 [No Abstract] [Full Text] [Related]
8. Intermittent androgen deprivation therapy may prolong the duration of androgen dependence of well-differentiated prostate cancer. Kaneko Y; Maekawa S; Arakaki R; Okada Y; Terada N; Nishimura K Hinyokika Kiyo; 2006 Apr; 52(4):259-64. PubMed ID: 16686352 [TBL] [Abstract][Full Text] [Related]
9. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation. Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL; J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219 [TBL] [Abstract][Full Text] [Related]
10. [Current strategies of intermittent hormone therapy in prostate cancer]. Kaprin AD; Pavlov AIu; Ivanov SA; Gafanov RA Vopr Onkol; 2011; 57(2):260-4. PubMed ID: 21809677 [TBL] [Abstract][Full Text] [Related]
11. Intermittent hormone therapy: its potential in early prostate cancer and intra-epithelial neoplasia. Oliver RT Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():399-404. PubMed ID: 10895186 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness of adjuvant intermittent endocrine therapy following neoadjuvant endocrine therapy and external beam radiation therapy in men with locally advanced prostate cancer. Yamanaka H; Ito K; Naito S; Tsukamoto T; Usami M; Fujimoto H; Matsuoka N; Fukui I; Harada M; Ohashi Y; Kotake T; Kakizoe T Prostate; 2005 Apr; 63(1):56-64. PubMed ID: 15468166 [TBL] [Abstract][Full Text] [Related]
13. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. Cherrier MM; Rose AL; Higano C J Urol; 2003 Nov; 170(5):1808-11. PubMed ID: 14532781 [TBL] [Abstract][Full Text] [Related]
15. Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience. Pether M; Goldenberg SL; Bhagirath K; Gleave M Can J Urol; 2003 Apr; 10(2):1809-14. PubMed ID: 12773232 [TBL] [Abstract][Full Text] [Related]
17. Intermittent androgen blockade should be regarded as standard therapy in prostate cancer. Seruga B; Tannock IF Nat Clin Pract Oncol; 2008 Oct; 5(10):574-6. PubMed ID: 18628739 [No Abstract] [Full Text] [Related]
18. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study. Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M; Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491 [TBL] [Abstract][Full Text] [Related]
19. Prostate cancer--management of disseminated disease (intermittent androgen suppression). Lobel B; Richard F Acta Chir Iugosl; 2005; 52(4):11-2. PubMed ID: 16673586 [No Abstract] [Full Text] [Related]
20. [Usefulness and positioning of MAB therapy for prostate cancer]. Akaza H; Chodak GW; Hirao Y Gan To Kagaku Ryoho; 2005 Oct; 32(10):1507-20. PubMed ID: 16227758 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]